论文部分内容阅读
目的探讨培菲康联合美沙拉嗪对于溃疡性结肠炎患者的临床疗效及炎症因子、免疫功能的影响。方法将2013年6月至2016年5月于津市市人民医院消化科确诊为溃疡性结肠炎的110例患者纳入研究并随机分组。对照组55例采用美沙拉嗪,观察组55例则联合培菲康治疗。比较两组临床疗效差异。结果治疗后,患者脓血便、腹痛、腹泻等症状积分及Baron内镜积分降低,但观察组改善更显著(P<0.05);对照组血清肿瘤坏死因子(TNF-a)、超敏C反应蛋白(Hs-CRP)、白介素-6(IL-6)等炎症指标均降低,CD3+T、CD4+T、CD4+/CD8+T等T淋巴亚群明显升高,但观察组改善更显著,P<0.05;对照组总有效率81.82%(45/55),观察组为94.56%(53/55),总有效率更高,P<0.05。结论培菲康联合美沙拉嗪治疗溃疡性结肠炎效果显著,可更好地改善肠道炎症反应,有助于免疫功能提高,值得推广。
Objective To investigate the effect of combination of Pefloxacin and mesalazine on the clinical efficacy, inflammatory factors and immune function in patients with ulcerative colitis. Methods A total of 110 patients with ulcerative colitis diagnosed in Department of Gastroenterology, Tianjin People’s Hospital from June 2013 to May 2016 were included in the study and randomly assigned. In the control group, 55 cases were treated with mesalazine, 55 cases in the observation group were treated with Peifei Kang. The difference of clinical efficacy between the two groups was compared. Results After treatment, the scores of pus and bloody stools, abdominal pain and diarrhea and Baron endoscopy scores decreased, but the improvement in the observation group was more significant (P <0.05). The serum levels of tumor necrosis factor (TNF), high sensitivity C reactive protein (Hs-CRP) and interleukin-6 (IL-6) were significantly decreased, while T lymphocyte subsets such as CD3 + T, CD4 + T and CD4 + / CD8 + T were significantly increased, but the improvement in the observation group was more significant <0.05. The total effective rate was 81.82% (45/55) in the control group and 94.56% (53/55) in the observation group. The total effective rate was higher (P <0.05). Conclusion Pefloxacin combined with mesalazine treatment of ulcerative colitis significant effect, can better improve intestinal inflammatory response, contribute to improve immune function, it is worth promoting.